Published in N Engl J Med on November 29, 1990
Predicting the functional effect of amino acid substitutions and indels. PLoS One (2012) 8.61
Guidelines for diagnosis of cystic fibrosis in newborns through older adults: Cystic Fibrosis Foundation consensus report. J Pediatr (2008) 5.19
Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. J Cyst Fibros (2008) 2.56
Cystic fibrosis transmembrane conductance regulator is an epithelial cell receptor for clearance of Pseudomonas aeruginosa from the lung. Proc Natl Acad Sci U S A (1997) 2.51
Genetic determination of exocrine pancreatic function in cystic fibrosis. Am J Hum Genet (1992) 2.48
Heritability of lung disease severity in cystic fibrosis. Am J Respir Crit Care Med (2007) 2.04
Cystic fibrosis identified by neonatal screening: incidence, genotype, and early natural history. Arch Dis Child (1993) 1.99
Modifier genes in Mendelian disorders: the example of cystic fibrosis. Ann N Y Acad Sci (2010) 1.87
Association of a nonsense mutation (W1282X), the most common mutation in the Ashkenazi Jewish cystic fibrosis patients in Israel, with presentation of severe disease. Am J Hum Genet (1992) 1.85
Generation of multipotent lung and airway progenitors from mouse ESCs and patient-specific cystic fibrosis iPSCs. Cell Stem Cell (2012) 1.72
Pulmonary outcome prediction (POP) tools for cystic fibrosis patients. Pediatr Pulmonol (2010) 1.71
Relative contribution of genetic and nongenetic modifiers to intestinal obstruction in cystic fibrosis. Gastroenterology (2006) 1.71
Cystic fibrosis genetics: from molecular understanding to clinical application. Nat Rev Genet (2014) 1.70
Classifying severity of cystic fibrosis lung disease using longitudinal pulmonary function data. Am J Respir Crit Care Med (2006) 1.63
Detection of cystic fibrosis transmembrane conductance regulator activity in early-phase clinical trials. Proc Am Thorac Soc (2007) 1.62
Role of tumor necrosis factor alpha in innate resistance to mouse pulmonary infection with Pseudomonas aeruginosa. Infect Immun (1995) 1.61
Contribution of genetic factors other than CFTR to disease severity in cystic fibrosis. Thorax (1998) 1.60
Endobronchial inflammation following Pseudomonas aeruginosa infection in resistant and susceptible strains of mice. Infect Immun (1995) 1.57
Complex two-gene modulation of lung disease severity in children with cystic fibrosis. J Clin Invest (2008) 1.57
Severe deficiency of cystic fibrosis transmembrane conductance regulator messenger RNA carrying nonsense mutations R553X and W1316X in respiratory epithelial cells of patients with cystic fibrosis. J Clin Invest (1991) 1.56
Pulmonary outcome in cystic fibrosis is influenced primarily by mucoid Pseudomonas aeruginosa infection and immune status and only modestly by genotype. Infect Immun (1999) 1.54
Expression of the cystic fibrosis transmembrane conductance regulator gene in cells of non-epithelial origin. Nucleic Acids Res (1991) 1.52
Molecular consequences of cystic fibrosis transmembrane regulator (CFTR) gene mutations in the exocrine pancreas. Gut (2003) 1.45
Mutations in the cystic fibrosis transmembrane regulator gene and in vivo transepithelial potentials. Am J Respir Crit Care Med (2006) 1.44
Variable deletion of exon 9 coding sequences in cystic fibrosis transmembrane conductance regulator gene mRNA transcripts in normal bronchial epithelium. EMBO J (1991) 1.40
Respiratory epithelial gene expression in patients with mild and severe cystic fibrosis lung disease. Am J Respir Cell Mol Biol (2006) 1.39
Molecular survey of a prevalent mutation, 985A-to-G transition, and identification of five infrequent mutations in the medium-chain Acyl-CoA dehydrogenase (MCAD) gene in 55 patients with MCAD deficiency. Am J Hum Genet (1991) 1.38
Lung phagocyte bactericidal function in strains of mice resistant and susceptible to Pseudomonas aeruginosa. Infect Immun (1996) 1.38
Neonatal screening for cystic fibrosis using immunoreactive trypsinogen and direct gene analysis: four years' experience. BMJ (1994) 1.35
Comparison of adherence of Pseudomonas aeruginosa to respiratory epithelial cells from cystic fibrosis patients and healthy subjects. Infect Immun (1992) 1.30
Patterns of GI disease in adulthood associated with mutations in the CFTR gene. Gut (2007) 1.29
Update on gene modifiers in cystic fibrosis. Curr Opin Pulm Med (2008) 1.29
Quantification of the relative contribution of environmental and genetic factors to variation in cystic fibrosis lung function. J Pediatr (2010) 1.29
Pathology of pancreatic and intestinal disorders in cystic fibrosis. J R Soc Med (1998) 1.28
Determinants of mild clinical symptoms in cystic fibrosis patients. Residual chloride secretion measured in rectal biopsies in relation to the genotype. J Clin Invest (1994) 1.23
Cystic fibrosis patients bearing both the common missense mutation Gly----Asp at codon 551 and the delta F508 mutation are clinically indistinguishable from delta F508 homozygotes, except for decreased risk of meconium ileus. Am J Hum Genet (1992) 1.22
Application of DNA analysis in a population-screening program for neonatal diagnosis of cystic fibrosis (CF): comparison of screening protocols. Am J Hum Genet (1993) 1.19
Cystic fibrosis genotypes and views on screening are both heterogeneous and population related. Am J Hum Genet (1992) 1.17
Effect of temperature on cystic fibrosis lung disease and infections: a replicated cohort study. PLoS One (2011) 1.16
Evidence that the ancestral haplotype in Australian hemochromatosis patients may be associated with a common mutation in the gene. Am J Hum Genet (1995) 1.15
The CLCA gene locus as a modulator of the gastrointestinal basic defect in cystic fibrosis. Hum Genet (2004) 1.14
Nine cystic fibrosis patients homozygous for the CFTR nonsense mutation R1162X have mild or moderate lung disease. J Med Genet (1992) 1.13
Interaction between a novel TGFB1 haplotype and CFTR genotype is associated with improved lung function in cystic fibrosis. Hum Mol Genet (2008) 1.12
Synthetic aminoglycosides efficiently suppress cystic fibrosis transmembrane conductance regulator nonsense mutations and are enhanced by ivacaftor. Am J Respir Cell Mol Biol (2014) 1.10
Meconium ileus caused by mutations in GUCY2C, encoding the CFTR-activating guanylate cyclase 2C. Am J Hum Genet (2012) 1.08
The cystic fibrosis transmembrane conductance regulator gene and ion channel function in patients with idiopathic pancreatitis. Hum Genet (2005) 1.08
Severity of chest disease in cystic fibrosis patients in relation to their genotypes. J Med Genet (1992) 1.06
Variants in the glutamate-cysteine-ligase gene are associated with cystic fibrosis lung disease. Am J Respir Crit Care Med (2006) 1.06
The TNFalpha receptor TNFRSF1A and genes encoding the amiloride-sensitive sodium channel ENaC as modulators in cystic fibrosis. Hum Genet (2006) 1.05
PTX3 genetic variations affect the risk of Pseudomonas aeruginosa airway colonization in cystic fibrosis patients. Genes Immun (2010) 1.01
A cystic fibrosis patient who is homozygous for the G85E mutation has very mild disease. J Med Genet (1991) 1.00
Strategies for identifying modifier genes in cystic fibrosis. Proc Am Thorac Soc (2007) 0.99
Modeling of nucleotide binding domains of ABC transporter proteins based on a F1-ATPase/recA topology: structural model of the nucleotide binding domains of the cystic fibrosis transmembrane conductance regulator (CFTR). J Bioenerg Biomembr (1997) 0.99
Homozygous nonsense mutation causing cystic fibrosis with uniparental disomy. Am J Hum Genet (1991) 0.98
Newborn screening. Clin Biochem Rev (2010) 0.98
Diagnosis of pancreatic adenocarcinoma by polymerase chain reaction from pancreatic secretions. Br J Cancer (1994) 0.97
Gene modifiers in cystic fibrosis. J Clin Invest (2008) 0.97
Methodology and applications of disease biomarker identification in human serum. Biomark Insights (2007) 0.97
Assessing the Disease-Liability of Mutations in CFTR. Cold Spring Harb Perspect Med (2012) 0.96
A novel exon in the cystic fibrosis transmembrane conductance regulator gene activated by the nonsense mutation E92X in airway epithelial cells of patients with cystic fibrosis. J Clin Invest (1994) 0.96
Cystic fibrosis-related diabetes: from CFTR dysfunction to oxidative stress. Clin Biochem Rev (2009) 0.96
The mannose binding lectin gene influences the severity of chronic liver disease in cystic fibrosis. J Med Genet (2001) 0.95
Increased prevalence of CFTR mutations and variants and decreased chloride secretion in primary sclerosing cholangitis. Hum Genet (2003) 0.95
Understanding the population structure of North American patients with cystic fibrosis. Clin Genet (2011) 0.95
Progression of pulmonary hyperinflation and trapped gas associated with genetic and environmental factors in children with cystic fibrosis. Respir Res (2006) 0.93
Phenotypic and genetic characterization of patients with features of "nonclassic" forms of cystic fibrosis. J Pediatr (2005) 0.91
CFTR mutation analysis and haplotype associations in CF patients. Mol Genet Metab (2011) 0.89
Histo-blood group gene polymorphisms as potential genetic modifiers of infection and cystic fibrosis lung disease severity. PLoS One (2009) 0.89
Classic respiratory disease but atypical diagnostic testing distinguishes adult presentation of cystic fibrosis. Chest (2009) 0.89
The cooperation between the autophagy machinery and the inflammasome to implement an appropriate innate immune response: do they regulate each other? Immunol Rev (2015) 0.88
Genetic influences on cystic fibrosis lung disease severity. Front Pharmacol (2013) 0.88
Pancreatic phenotype in infants with cystic fibrosis identified by mutation screening. Arch Dis Child (2007) 0.88
Atypical cystic fibrosis--diagnostic and management dilemmas. J R Soc Med (2003) 0.88
Disease-modifying genes and monogenic disorders: experience in cystic fibrosis. Appl Clin Genet (2014) 0.88
Prediction of cellular immune responses against CFTR in patients with cystic fibrosis after gene therapy. Am J Respir Cell Mol Biol (2007) 0.87
Disease modifying genes in cystic fibrosis: therapeutic option or one-way road? Naunyn Schmiedebergs Arch Pharmacol (2006) 0.87
Recent advances in cystic fibrosis research. J R Soc Med (1993) 0.87
New and emerging targeted therapies for cystic fibrosis. BMJ (2016) 0.87
Diabetes in cystic fibrosis. J R Soc Med (1999) 0.86
Genetic modifiers of nutritional status in cystic fibrosis. Am J Clin Nutr (2012) 0.86
Functional analysis of synonymous substitutions predicted to affect splicing of the CFTR gene. J Cyst Fibros (2012) 0.85
Cystic fibrosis mutations among African Americans in the southeastern United States. J Natl Med Assoc (1995) 0.85
Changes in transcriptome of native nasal epithelium expressing F508del-CFTR and intersecting data from comparable studies. Respir Res (2013) 0.85
From genotype to phenotype: genetics and medical practice in the new millennium. Philos Trans R Soc Lond B Biol Sci (1999) 0.85
Annual review or continuous assessment? J R Soc Med (1996) 0.84
Similar levels of mRNA from the W1282X and the delta F508 cystic fibrosis alleles, in nasal epithelial cells. J Clin Invest (1994) 0.84
Sources of Variation in Sweat Chloride Measurements in Cystic Fibrosis. Am J Respir Crit Care Med (2016) 0.83
Cystic fibrosis modifier genes. J R Soc Med (2005) 0.83
The cystic fibrosis of exocrine pancreas. Cold Spring Harb Perspect Med (2013) 0.83
Long-term gas exchange characteristics as markers of deterioration in patients with cystic fibrosis. Respir Res (2009) 0.81
Relationship Between Fat-Soluble Vitamin Supplementation and Blood Concentrations in Adolescent and Adult Patients With Cystic Fibrosis. Nutr Clin Pract (2014) 0.81
Apical CFTR expression in human nasal epithelium correlates with lung disease in cystic fibrosis. PLoS One (2013) 0.81
CFTR Modulators for the Treatment of Cystic Fibrosis. P T (2014) 0.81
Rescue of NBD2 mutants N1303K and S1235R of CFTR by small-molecule correctors and transcomplementation. PLoS One (2015) 0.81
TNF-alpha promoter polymorphism in relation to TNF-alpha production and clinical status in cystic fibrosis. Lung (2006) 0.81
Can Cystic Fibrosis Patients Finally Catch a Breath With Orkambi? Clin Pharmacol Ther (2016) 0.81
Frontiers in research on cystic fibrosis: understanding its molecular and chemical basis and relationship to the pathogenesis of the disease. J Bioenerg Biomembr (1997) 0.80
New possibilities for population control of cystic fibrosis. Bull World Health Organ (1992) 0.80
Genetics and treatment options for recurrent acute and chronic pancreatitis. Curr Treat Options Gastroenterol (2014) 0.80
Helicobacter pylori and Clostridium difficile in cystic fibrosis patients. Dig Dis Sci (2006) 0.80
Identification of the cystic fibrosis gene: genetic analysis. Science (1989) 33.61
Pseudomonas cepacia infection in cystic fibrosis: an emerging problem. J Pediatr (1984) 9.61
Management of asthma: a consensus statement. Arch Dis Child (1989) 7.04
Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet (1997) 6.83
The complete BRCA2 gene and mutations in chromosome 13q-linked kindreds. Nat Genet (1996) 6.43
Cystic fibrosis locus defined by a genetically linked polymorphic DNA marker. Science (1985) 5.81
Mutations in the human Sonic Hedgehog gene cause holoprosencephaly. Nat Genet (1996) 5.70
Prediction of mortality in patients with cystic fibrosis. N Engl J Med (1992) 5.46
A cluster of cystic fibrosis mutations in the first nucleotide-binding fold of the cystic fibrosis conductance regulator protein. Nature (1990) 5.42
A polymorphic DNA marker linked to cystic fibrosis is located on chromosome 7. Nature (1985) 5.07
A candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet (2001) 5.06
Identification of mutations in regions corresponding to the two putative nucleotide (ATP)-binding folds of the cystic fibrosis gene. Proc Natl Acad Sci U S A (1990) 4.74
Mutation analysis for heterozygote detection and the prenatal diagnosis of cystic fibrosis. N Engl J Med (1990) 4.60
A 1.5 million-base pair inversion polymorphism in families with Williams-Beuren syndrome. Nat Genet (2001) 4.58
A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto. J Clin Epidemiol (1988) 4.41
Genomic DNA sequence of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Genomics (1991) 4.27
MADR2 maps to 18q21 and encodes a TGFbeta-regulated MAD-related protein that is functionally mutated in colorectal carcinoma. Cell (1996) 4.13
Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice. Nat Med (1997) 4.10
Correction of the cystic fibrosis defect in vitro by retrovirus-mediated gene transfer. Cell (1990) 3.70
Specific and redundant functions of Gli2 and Gli3 zinc finger genes in skeletal patterning and development. Development (1997) 3.66
Expression of the cystic fibrosis gene in non-epithelial invertebrate cells produces a regulated anion conductance. Cell (1991) 3.56
Identification of Sonic hedgehog as a candidate gene responsible for holoprosencephaly. Nat Genet (1996) 3.50
Cone-rod dystrophy due to mutations in a novel photoreceptor-specific homeobox gene (CRX) essential for maintenance of the photoreceptor. Cell (1997) 3.42
Longitudinal analysis of pulmonary function decline in patients with cystic fibrosis. J Pediatr (1997) 3.38
Common origins of BRCA1 mutations in Canadian breast and ovarian cancer families. Nat Genet (1994) 3.38
Cystic fibrosis: genotypic and phenotypic variations. Annu Rev Genet (1995) 3.27
Multi-ion pore behaviour in the CFTR chloride channel. Nature (1993) 3.14
A suggested nomenclature for designating mutations. Hum Mutat (1993) 3.10
Comparative analysis of the gene-dense ACHE/TFR2 region on human chromosome 7q22 with the orthologous region on mouse chromosome 5. Nucleic Acids Res (2001) 2.89
BRCA2 germline mutations in male breast cancer cases and breast cancer families. Nat Genet (1996) 2.75
High-resolution mapping of mammalian genes by in situ hybridization to free chromatin. Proc Natl Acad Sci U S A (1992) 2.72
Rapid nonradioactive detection of the major cystic fibrosis mutation. Am J Hum Genet (1990) 2.72
Bronchial reactivity in cystic fibrosis. Pediatrics (1978) 2.70
Structure and chromosomal localization of the human constitutive endothelial nitric oxide synthase gene. J Biol Chem (1993) 2.69
Modulation of disease severity in cystic fibrosis transmembrane conductance regulator deficient mice by a secondary genetic factor. Nat Genet (1996) 2.65
A mutation in CFTR produces different phenotypes depending on chromosomal background. Nat Genet (1993) 2.64
Introduction and recovery of a selectable bacterial gene from the genome of mammalian cells. Mol Cell Biol (1982) 2.59
A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene (1993) 2.59
Mutations in the homeodomain of the human SIX3 gene cause holoprosencephaly. Nat Genet (1999) 2.57
Standards of pulmonary function in children. Am Rev Respir Dis (1969) 2.56
Consensus on the use and interpretation of cystic fibrosis mutation analysis in clinical practice. J Cyst Fibros (2008) 2.56
Mutations in a gene encoding a novel protein tyrosine phosphatase cause progressive myoclonus epilepsy. Nat Genet (1998) 2.51
The risk of cancer among patients with cystic fibrosis. Cystic Fibrosis and Cancer Study Group. N Engl J Med (1995) 2.49
Genetic determination of exocrine pancreatic function in cystic fibrosis. Am J Hum Genet (1992) 2.48
Sustained-release theophylline for childhood asthma: evidence for circadian variation of theophylline pharmacokinetics. J Pediatr (1981) 2.41
Modes of DAPI banding and simultaneous in situ hybridization. Chromosoma (1993) 2.38
Two patients with cystic fibrosis, nonsense mutations in each cystic fibrosis gene, and mild pulmonary disease. N Engl J Med (1990) 2.37
Pulmonary function abnormalities in symptom-free children after bronchiolitis. Pediatrics (1977) 2.32
Characterization of the human beta-crystallin gene Hu beta A3/A1 reveals ancestral relationships among the beta gamma-crystallin superfamily. J Biol Chem (1986) 2.31
Characterization of the split hand/split foot malformation locus SHFM1 at 7q21.3-q22.1 and analysis of a candidate gene for its expression during limb development. Hum Mol Genet (1996) 2.29
Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa. J Pediatr (1990) 2.28
Genetic ablation: targeted expression of a toxin gene causes microphthalmia in transgenic mice. Science (1987) 2.27
Permeability of wild-type and mutant cystic fibrosis transmembrane conductance regulator chloride channels to polyatomic anions. J Gen Physiol (1997) 2.26
Congenital bilateral absence of vas deferens in the absence of cystic fibrosis. Lancet (1994) 2.22
Association of respiratory viral infections with pulmonary deterioration in patients with cystic fibrosis. N Engl J Med (1984) 2.22
Molecular characterization of a common fragile site (FRA7H) on human chromosome 7 by the cloning of a simian virus 40 integration site. Proc Natl Acad Sci U S A (1998) 2.16
Identification of mutations in exons 1 through 8 of the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Genomics (1991) 2.07
High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease. Lancet (1987) 2.05
Five- to seven-year course of pulmonary function in cystic fibrosis. Am Rev Respir Dis (1976) 2.03
Gene expression: chemical synthesis of E. coli ribosome binding sites and their use in directing the expression of mammalian proteins in bacteria. Nucleic Acids Res (1982) 2.01
Pulmonary function and bronchial hyperreactivity in long-term survivors of bronchopulmonary dysplasia. Pediatrics (1981) 2.00
Ultrastructure of airways in children with asthma. Histopathology (1978) 1.97
A randomized controlled trial of a 3-year home exercise program in cystic fibrosis. J Pediatr (2000) 1.93
Methods for analysis of multiple cystic fibrosis mutations. Hum Genet (1991) 1.88
The gene mutated in adult-onset type II citrullinaemia encodes a putative mitochondrial carrier protein. Nat Genet (1999) 1.87
Identification and regional localization of DNA markers on chromosome 7 for the cloning of the cystic fibrosis gene. Am J Hum Genet (1988) 1.80
Binding of Pseudomonas cepacia to normal human intestinal mucin and respiratory mucin from patients with cystic fibrosis. J Clin Invest (1992) 1.80
Hepatic abscess and cystic fibrosis. Postgrad Med J (1988) 1.77
Role of conventional physiotherapy in cystic fibrosis. J Pediatr (1988) 1.75
Impaired chloride secretion, as well as bicarbonate secretion, underlies the fluid secretory defect in the cystic fibrosis pancreas. Gastroenterology (1988) 1.75
Pancreatitis in patients with organic acidemias. J Pediatr (1994) 1.73
Identification of revertants for the cystic fibrosis delta F508 mutation using STE6-CFTR chimeras in yeast. Cell (1993) 1.72
Correlation of sweat chloride concentration with classes of the cystic fibrosis transmembrane conductance regulator gene mutations. J Pediatr (1995) 1.70
The HIV information project for transfusion recipients a decade after transfusion. Arch Pediatr Adolesc Med (1995) 1.70
Pancreatic fluid secretion and protein hyperconcentration in cystic fibrosis. N Engl J Med (1985) 1.67
DNA marker haplotype association with pancreatic sufficiency in cystic fibrosis. Am J Hum Genet (1989) 1.66